Xponance Inc. Has $678,000 Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Xponance Inc. trimmed its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 7.2% during the fourth quarter, Holdings Channel reports. The firm owned 12,115 shares of the company’s stock after selling 945 shares during the period. Xponance Inc.’s holdings in 10x Genomics were worth $678,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its stake in shares of 10x Genomics by 51.6% in the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock valued at $44,000 after acquiring an additional 266 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of 10x Genomics in the third quarter valued at approximately $146,000. Bleakley Financial Group LLC bought a new position in shares of 10x Genomics in the fourth quarter valued at approximately $234,000. Simplicity Solutions LLC bought a new position in shares of 10x Genomics in the fourth quarter valued at approximately $234,000. Finally, AXQ Capital LP bought a new position in shares of 10x Genomics in the third quarter valued at approximately $280,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 4,660 shares of 10x Genomics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $44.00, for a total transaction of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares of the company’s stock, valued at approximately $37,087,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Justin J. Mcanear sold 1,865 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the transaction, the chief financial officer now owns 95,240 shares of the company’s stock, valued at approximately $4,413,421.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Serge Saxonov sold 4,660 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $44.00, for a total transaction of $205,040.00. Following the completion of the transaction, the chief executive officer now directly owns 842,900 shares of the company’s stock, valued at approximately $37,087,600. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,959 shares of company stock valued at $592,806. Company insiders own 10.65% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of research analyst reports. Barclays cut their target price on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Stifel Nicolaus dropped their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Moderate Buy” and a consensus target price of $60.22.

10x Genomics Stock Performance

TXG stock opened at $27.59 on Friday. The company has a 50 day moving average price of $37.70 and a 200 day moving average price of $42.52. 10x Genomics, Inc. has a fifty-two week low of $26.30 and a fifty-two week high of $63.57.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The business had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. During the same period in the prior year, the firm posted ($0.15) EPS. 10x Genomics’s revenue was up 17.8% on a year-over-year basis. As a group, equities analysts predict that 10x Genomics, Inc. will post -1.47 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.